Healthcare / Drug Manufacturers - Specialty & GenericKuala Lumpur
$0.69
+0.01 (+1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $17.0M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$153M
P/E
13.8x
↓EV/EBITDA
4.8x
↓ROE
8.1%
↑Gross Margin
31.3%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.1%
FCF CAGR
—
FCF margin
16.2%
FCF / Net income
2.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $223.7M · net income $14.2M · FCF $36.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $223.7M | $223.7M | $211.4M | $202.9M | $198.2M |
| Net Income | $14.2M | $14.2M | $12.3M | $12.1M | $12.7M |
| EBITDA | $26.3M | $26.3M | $24.2M | $23.9M | $24.1M |
| EPS | — | — | 0.04 | 0.04 | 0.04 |
| Gross Margin | 31.3% | 31.3% | 28.1% | 26.7% | 27.2% |
| Operating Margin | 11.4% | 11.4% | 9.7% | 9.8% | 10.4% |
| Net Margin | 6.3% | 6.3% | 5.8% | 6.0% | 6.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.14 | 0.20 | 0.19 |
| Current Ratio | 4.11 | 4.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $36.3M | $36.3M | $17.0M | $5.5M | $-6.4M |
| Returns | |||||
| ROE | 8.1% | 8.1% | 7.3% | 7.5% | 8.3% |
| Valuation | |||||
| P/E | 13.80 | 13.80 | 16.42 | 17.46 | 15.65 |
| EV/EBITDA | 4.82 | 4.82 | 8.23 | 9.15 | 8.81 |
| P/B | 0.86 | 0.86 | 1.20 | 1.31 | 1.30 |
| Growth & Yield | |||||
| Revenue Growth | 5.8% | 5.8% | 4.2% | 2.4% | — |
| EPS Growth | — | — | 1.7% | -6.3% | — |
| Dividend Yield | 3.6% | 3.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.04 → n/d
Residual
+8.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.